FDA Approved: KISQALI — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for KISQALI (ribociclib) from Novartis, updating the label to include an additional breast cancer indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

SUPPL AP for KISQALI (RIBOCICLIB)